TY - JOUR
T1 - Autumn royal and egnatia grape extracts differently modulate cell proliferation in human colorectal cancer cells
AU - Gigante, Isabella
AU - Milella, Rosa Anna
AU - Tutino, Valeria
AU - Debiase, Giambattista
AU - Notarangelo, Luciano
AU - Giannandrea, Maria Angela
AU - De Nunzio, Valentina
AU - Orlando, Antonella
AU - D’alessandro, Rosalba
AU - Caruso, Maria Gabriella
AU - Notarnicola, Maria
N1 - Funding Information:
The study was supported by RC 2019-2021, Prog. CS019 (D.D.G. n. 748/2018).
Publisher Copyright:
© 2020 Bentham Science Publishers.
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020
Y1 - 2020
N2 - Objective: Polyphenols extracted by table grape have been demonstrated to decrease cell proliferation in vitro and to exert anti-atherosclerotic and antithrombotic activities, regulating cell func-tions. A grape polyphenolic profile is affected by climate as well as a grape cultivar. This study was aimed to characterize the berry skin polyphenolic composition, antioxidant activity and antiprolifera-tive properties of two black grape cultivars, Autumn Royal and Egnatia. Methods: The phenolic composition of grape skin extracts (GSEs) was determined by HPLC analyses. The antioxidant activity was determined using DPPH, ABTS and ORAC tests. Caco2, HT29 and SW480 human colon cancer cell lines were used to test the effects of GSEs in vitro. Cell proliferation and cell cycle were assessed with the MTT method and a Muse cell analyzer, respectively. qPCR and Western Blotting analysis were used to evaluate gene and protein expression, respectively. Results: The total polyphenolic content and the total antioxidant capacity were significantly higher in Autumn Royal than in Egnatia. However, table grape Egnatia showed greater ability to affect cell proliferation and apoptosis, as well as to exert a growth arrest in the S phase of the cell cycle, particularly in the Caco2 cell line. Conclusion: These data suggest that the new grape variety Egnatia is an interesting source of phenolic compounds that could be of interest in the food and pharmaceutical industries.
AB - Objective: Polyphenols extracted by table grape have been demonstrated to decrease cell proliferation in vitro and to exert anti-atherosclerotic and antithrombotic activities, regulating cell func-tions. A grape polyphenolic profile is affected by climate as well as a grape cultivar. This study was aimed to characterize the berry skin polyphenolic composition, antioxidant activity and antiprolifera-tive properties of two black grape cultivars, Autumn Royal and Egnatia. Methods: The phenolic composition of grape skin extracts (GSEs) was determined by HPLC analyses. The antioxidant activity was determined using DPPH, ABTS and ORAC tests. Caco2, HT29 and SW480 human colon cancer cell lines were used to test the effects of GSEs in vitro. Cell proliferation and cell cycle were assessed with the MTT method and a Muse cell analyzer, respectively. qPCR and Western Blotting analysis were used to evaluate gene and protein expression, respectively. Results: The total polyphenolic content and the total antioxidant capacity were significantly higher in Autumn Royal than in Egnatia. However, table grape Egnatia showed greater ability to affect cell proliferation and apoptosis, as well as to exert a growth arrest in the S phase of the cell cycle, particularly in the Caco2 cell line. Conclusion: These data suggest that the new grape variety Egnatia is an interesting source of phenolic compounds that could be of interest in the food and pharmaceutical industries.
KW - Cell cycle
KW - Cell proliferation
KW - Colorectal cancer
KW - Human cell lines
KW - Polyphenols
KW - Table grape
UR - http://www.scopus.com/inward/record.url?scp=85089004508&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85089004508&partnerID=8YFLogxK
U2 - 10.2174/1871530320666200421102418
DO - 10.2174/1871530320666200421102418
M3 - Article
C2 - 32316903
AN - SCOPUS:85089004508
VL - 20
SP - 1740
EP - 1750
JO - Endocrine, Metabolic and Immune Disorders - Drug Targets
JF - Endocrine, Metabolic and Immune Disorders - Drug Targets
SN - 1871-5303
IS - 10
ER -